CORDIS
EU research results

CORDIS

English EN

A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe's top class vascular research to find new treatment strategies for vascular anomalies

Project information

Grant agreement ID: 814316

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    28 February 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 792 135,60

  • EU contribution

    € 3 792 135,60

Coordinated by:

DE DUVE INSTITUTE

Belgium

Objective

Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, and for which effective treatments are lacking. The European V.A. Cure network aims to address this unmet medical need by uncovering core mechanisms of disease initiation and maintenance and by leveraging this information for establishing novel therapeutic strategies for VAs.
V.A. Cure has assembled 7 world-leading academic laboratories and 5 companies, which will apply an intersectoral four-step approach: (1) identification of novel genes involved in VAs in patients, (2) dissection of molecular mechanisms behind the diseases by in vitro modelling, (3) in-depth analysis of tissular mechanisms in pathophysiological conditions through in vivo models, and (4) pre-clinical testing of identified treatment strategies. The knowledge gained will not only be relevant for VAs but also for understanding aberrant vascular function in other vascular-related diseases.
The composition of V.A. Cure and close interaction between the 14 ESRs, through secondments in academia and industry, guarantee a unique intersectoral training program at the highest level, ensuring a comprehensive perception of research and drug/technology development in pharma industry/biotech and academia. ESRs will be trained in a plethora of cutting-edge technologies including next-generation sequencing (up to single-cell RNA-Seq), CRISPR-Cas genome editing, generation of animal models with inducible deletion and mosaic analyses, generation of iPSCs, microfluidics, in vivo phage display to identify endothelial targets, and light sheet-, confocal-, and multiphoton live-imaging. In combination with advanced training in management and communication including writing, presentation, e-media and outreach, the graduates of the V.A. Cure network will be future leaders in vascular research, and also highly competitive candidates for positions outside academia.

Coordinator

DE DUVE INSTITUTE

Address

Avenue Hippocrate 75
1200 Bruxelles

Belgium

Activity type

Research Organisations

EU Contribution

€ 512 640

Participants (9)

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 563 965,92

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 252 788,40

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 281 982,96

UNIVERSITAET POTSDAM

Germany

EU Contribution

€ 505 576,80

OULUN YLIOPISTO

Finland

EU Contribution

€ 280 805,76

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 549 604,08

SINGH PRATEEK

Finland

EU Contribution

€ 280 805,76

ASTRAZENECA AB

Sweden

EU Contribution

€ 563 965,92

TAMPEREEN YLIOPISTO

Finland

Partners (8)

TAMPEREEN KORKEAKOULUSAATIO SR

Finland

Sysmex Inostics GmbH

Germany

BAYER AKTIENGESELLSCHAFT

Germany

Perimed AB

Sweden

LLS ROWIAK LASERLABSOLUTIONS GMBH

Germany

BELGIAN VASCULAR ANOMALY PATIENT ASSOCIATION

Belgium

MOLECULINK AB

Sweden

CLINIQUES UNIVERSITAIRES SAINT-LUC

Belgium

Project information

Grant agreement ID: 814316

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    28 February 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 792 135,60

  • EU contribution

    € 3 792 135,60

Coordinated by:

DE DUVE INSTITUTE

Belgium